Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972056 · ClinicalTrials.gov registry record · Phase 4
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
A Phase 4 study of Migraine, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 1,335
- Enrollment target
- 18
- Study locations
NCT06972056 is a Phase 4 study of Migraine that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,335 participants, above the 345-participant average among 102 other Migraine trials with a reported enrollment target (287% higher). The trial reports 18 study locations across 15 states.
The verdict
NCT06972056, a Phase 4 study of Migraine, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,335 participants
- Enrollment target
- 18
- Study locations
Study Summary
This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits.
Conditions Studied
Interventions
- DRUG Atogepant 60 mg
- DRUG Propranolol 160 mg
- DRUG Topiramate 100 mg
Study Locations (18)
Arizona
- Northern Arizona Healthcare - Flagstaff
- Mayo Clinic Arizona - Phoenix
California
- USC Keck - Los Angeles
- Clinical Research Institute - Los Angeles
Florida
- Mayo Clinic Florida - Jacksonville
- Apple Med Research - Miami
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University St Louis - St Louis
Nevada
- Advanced Research Institute Reno - Reno
New Jersey
- JFK Neuroscience Institute - Edison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,335 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06972056
The ClinicalTrials.gov registry entry for NCT06972056 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 1,335 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 345-participant average among 102 other Migraine trials with a reported enrollment target (287% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which Atogepant 60 mg is the first listed.
NCT06972056 reports 18 study locations spanning 15 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06972056 about?
NCT06972056 is a clinical study titled "Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study". This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerab...
What is the current status of trial NCT06972056?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 1,335 participants. The study started on 2025-07-09. Estimated completion is 2029-12-01.
What conditions does trial NCT06972056 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06972056?
The interventions under investigation include: Atogepant 60 mg (DRUG), Propranolol 160 mg (DRUG), Topiramate 100 mg (DRUG).
Who is sponsoring clinical trial NCT06972056?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972056 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.